This study was conducted to determine if there were any advantages to a form of selenium derived from Baker’s Yeast known as SelenoExcell®.
The study found that the yeast-derived selenium reduced prostate cancers incidence by 52% and cancer mortality by 50%.
A study on another form of selenium, known as selenomethionine, found no such benefit, so the form of selenium is of particular importance, especially for cancer prevention.
SelenoExcell® showed the most benefit for those who had the lowest blood levels of selenium at the beginning of the trial.
Another analysis of the data by the same authors also showed selenium supplementation resulted in cancer perevention.
